More than 500 members of the myasthenia gravis (MG) rare disease community will come together this week in-person and ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

Sunshine Cruz recently revealed that she’s battling an autoimmune disease called myasthenia gravis. In an Instagram post, the ...

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. This CME program is designed to enhance neurologists ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

Rozanolixizumab is a high-affinity humanized immunoglobulin G4 monoclonal antibody and Fc receptor blocker approved to treat ...

Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline, were re-randomized 1:1:1 to batoclimab (340mg weekly ...